Genio Hypoglossal Nerve Stimulation

Genio and Inspire are both FDA-approved hypoglossal nerve stimulation systems, but they differ in two main structural ways. Genio delivers bilateral stimulation to both sides of the tongue, while Inspire delivers unilateral, single-sided stimulation. Genio also uses a single, battery-free implant powered and controlled by an external, wearable component, while Inspire uses a fully implanted battery and pulse generator controlled with a small handheld remote.

Bilateral stimulation means the device activates the hypoglossal nerve on both sides of the tongue rather than one side only, as unilateral systems like Inspire do. Whether bilateral stimulation offers a meaningful clinical advantage over unilateral stimulation for a given patient has not been established in head-to-head evidence; it is a structural difference between the two systems rather than a proven superiority of one over the other.

Rather than implanting a battery and pulse generator inside the body, Genio uses a small implanted lead paired with an external component worn on the outside of the neck during sleep. That wearable powers the implant and delivers the stimulation signal, and it is reportedly able to be upgraded over time without requiring another surgical procedure, since the implanted portion itself is battery-free.

Genio's FDA-approved indication covers adults with moderate to severe obstructive sleep apnea, an AHI between 15 and 65, who have failed, refused, or cannot tolerate PAP therapies such as CPAP. Additional eligibility, including airway anatomy and other individual factors, is confirmed through evaluation with a sleep physician rather than from these criteria alone.

Genio received FDA approval in August 2025, based on data from the DREAM trial. It is a newer system than Inspire, which was originally approved in 2014.

Coverage is not guaranteed and varies by plan. FDA approval, Medicare coverage policy, and individual private insurance requirements are separate standards, and meeting one does not guarantee meeting the others. Confirming coverage for a specific patient requires checking with that patient's insurer directly.

The Genio implant is reported to be compatible with both 1.5T and 3T MRI scanning, which are the field strengths used in most clinical MRI machines. Patients with the device should still inform any imaging facility that they have an implanted device before scanning.

Implantation is a surgical procedure performed by a trained surgeon, generally followed by a healing period before the system is activated. As with any implanted device, specific recovery timelines and restrictions are individualized and should be discussed directly with the surgical and sleep medicine team involved in a patient's care.

CPAP uses continuous air pressure delivered through a mask to hold the airway open mechanically, and it is typically the first treatment tried for moderate to severe obstructive sleep apnea. Genio is a surgically placed nerve stimulation system generally considered afterward, for patients who have failed, refused, or cannot tolerate PAP therapy, and it works by stimulating the airway's own muscles rather than applying external pressure.

This page is intended as general patient education about Genio as an FDA-approved treatment option, and it does not confirm that Genio implantation or management is currently offered in a specific practice. Patients interested in Genio specifically should ask directly about current availability during a consultation.